Cardiac Patch with Bioink Can Repair the Heart
3D bioprinting using bioink from engineered stem cells enables treatment of myocardial infarction and other cardiovascular diseases.
The heart pumps blood to the entire body by repeated contraction and relaxation of the heart muscles. Human stem cells are used in the clinical therapies of a dead heart, which happens when a blood vessel is clogged or whole or a part of the heart muscle is damaged. The clinical use of human bone marrow-derived mesenchymal stem cells (BM-MSCs) has been expanded but failure of the transplanted stem cells in the heart still remains a problem.
A research team has developed a cardiac patch with bioink that enhances the functionality of stem cells to regenerate blood vessels, which in turn improves the myocardial infarction affected area.
The researchers mixed genetically engineered stem cells (genetically engineered hepatocyte growth factor-expressing MSCs, HGF-eMSCs) to make bioink in the form of a patch and introduced a new therapy by transplanting it to a damaged heart. The new strategy — called in vivo priming — refers to the principle that maximized function of MSCs is maintained in vivo as well as through its exposure to the growth factor secreted by the genetically engineered stem cells.
The team first genetically engineered the existing BM-MSCs to produce hepatocyte growth factor to improve the therapeutic potential of stem cells. The HGF-eMSCs were then mixed with BM-MSCs to make the bioink. They transplanted the cardiac patch with this bioink to the heart muscle affected by myocardial infarction. Considering the limited number of cells that could be transferred, they used heart-derived extracellular matrix bioink to make a cardiac patch.
Implanted cells in the patch survived longer in vivo and had more myocardiocytes survive than the only BM-MSCs transplanted experimental group. This was because the secretion of cytokine, which helps formation of blood vessels and cell growth, was maximized and delivered nutrients that promoted vascular regeneration and enhanced survival of the myocardiocytes.
The team anticipates that the new method could be a breakthrough treatment of myocardial infarction since the implanted stem cells through HGF-eM-SCs ultimately enhanced vascular regeneration and improved the myocardial infarction affected area.
For more information, contact Professor Jinah Jang at
Top Stories
INSIDERManned Systems
Turkey's KAAN Combat Aircraft Completes First Flight - Mobility Engineering...
INSIDERMaterials
FAA Expands Boeing 737 Investigation to Manufacturing and Production Lines -...
INSIDERImaging
New Video Card Enables Supersonic Vision System for NASA's X-59 Demonstrator -...
INSIDERManned Systems
Stratolaunch Approaches Hypersonic Speed in First Powered TA-1 Test Flight -...
INSIDERUnmanned Systems
Army Ends Future Attack and Reconnaissance Helicopter Development Program -...
ArticlesEnergy
Can Solid-State Batteries Commercialize by 2030? - Mobility Engineering...
Webcasts
AR/AI
From Data to Decision: How AI Enhances Warfighter Readiness
Energy
April Battery & Electrification Summit
Manufacturing & Prototyping
Tech Update: 3D Printing for Transportation in 2024
Test & Measurement
Building an Automotive EMC Test Plan
Manufacturing & Prototyping
The Moon and Beyond from a Thermal Perspective
Software
Mastering Software Complexity in Automotive: Is Release Possible...